header logo image


Page 25«..1020..24252627..30..»

Archive for April, 2020

What Is GeneReach Biotechnologys (GTSM:4171) P/E Ratio After Its Share Price Rocketed? – Simply Wall St

Sunday, April 12th, 2020

Its great to see GeneReach Biotechnology (GTSM:4171) shareholders have their patience rewarded with a 56% share price pop in the last month. Zooming out, the annual gain of 150% knocks our socks off.

Assuming no other changes, a sharply higher share price makes a stock less attractive to potential buyers. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). The implication here is that deep value investors might steer clear when expectations of a company are too high. One way to gauge market expectations of a stock is to look at its Price to Earnings Ratio (PE Ratio). Investors have optimistic expectations of companies with higher P/E ratios, compared to companies with lower P/E ratios.

See our latest analysis for GeneReach Biotechnology

We can tell from its P/E ratio of 49.49 that there is some investor optimism about GeneReach Biotechnology. As you can see below, GeneReach Biotechnology has a higher P/E than the average company (19.0) in the medical equipment industry.

GeneReach Biotechnologys P/E tells us that market participants think the company will perform better than its industry peers, going forward. The market is optimistic about the future, but that doesnt guarantee future growth. So further research is always essential. I often monitor director buying and selling.

Probably the most important factor in determining what P/E a company trades on is the earnings growth. If earnings are growing quickly, then the E in the equation will increase faster than it would otherwise. And in that case, the P/E ratio itself will drop rather quickly. A lower P/E should indicate the stock is cheap relative to others and that may attract buyers.

In the last year, GeneReach Biotechnology grew EPS like Taylor Swift grew her fan base back in 2010; the 141% gain was both fast and well deserved.

Dont forget that the P/E ratio considers market capitalization. That means it doesnt take debt or cash into account. Theoretically, a business can improve its earnings (and produce a lower P/E in the future) by investing in growth. That means taking on debt (or spending its cash).

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

Since GeneReach Biotechnology holds net cash of NT$177m, it can spend on growth, justifying a higher P/E ratio than otherwise.

GeneReach Biotechnologys P/E is 49.5 which is way above average (14.9) in its market. Its net cash position is the cherry on top of its superb EPS growth. So based on this analysis wed expect GeneReach Biotechnology to have a high P/E ratio. What is very clear is that the market has become significantly more optimistic about GeneReach Biotechnology over the last month, with the P/E ratio rising from 31.7 back then to 49.5 today. If you like to buy stocks that have recently impressed the market, then this one might be a candidate; but if you prefer to invest when there is blood in the streets, then you may feel the opportunity has passed.

When the market is wrong about a stock, it gives savvy investors an opportunity. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course you might be able to find a better stock than GeneReach Biotechnology. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
What Is GeneReach Biotechnologys (GTSM:4171) P/E Ratio After Its Share Price Rocketed? - Simply Wall St

Read More...

Biotech Firms May Be Key To Beating The Coronavirus, But They’re Not Immune To Financial Worry – WBUR

Sunday, April 12th, 2020

Scott Robinson used to be an investment banker, so he has a pretty good idea why it's tough these days to raise money for his Cambridge biotechnology startup, MicroQuin even though the company believes its approach to fighting cancer could show promise against the coronavirus.

"At the moment, a lot of the funding has really been allocated to things that people are thinking are quick wins stuff like drug repurposing or vaccinations," he said.

For a handful of drugmakers taking on the coronavirus, fundraising is no problem right now. But for many other Massachusetts biotechs, the pandemic threatens to stop the flow of money.

If you're a company like MicroQuin, and you don't have a coronavirus vaccine candidate or a drug ready to test against COVID-19 good luck getting new financing.

And there's no telling when investors will feel comfortable spending again.

"We've seen many investors sort of push the pause button for the next quarter, as they assess the market," saidJonathan Norris, a managing director at Silicon Valley Bank. He spoke this week on a virtual panel organized by LabCentral, the Kendall Square workspace where Robinson's company and about 70 others are based.

"We just don't know how long this pandemic is going to last," Norris said. "The big financial questions that investors are talking about are, 'What's going to happen in the public markets? Will IPOs happen?'"

Initial public offerings of stock can be critical to biotechs. They often infuse cash into young firms that have raised venture capital but don't yet have any FDA-approved drugs to produce revenue.

The Nasdaq Biotechnology Index has recovered some losses, after falling more than 20% last month. But it's still a scary time, said Robert Urban, the former head of Johnson & Johnson's innovation division. J&J has secured a $1 billiondeal including federal grants to try to develop a vaccine, but most companies aren't in that position.

"We have some tough days ahead and maybe tough months ahead," Urban said of the biotech industry. "So, anyone who's running a business a life science business, in some ways, may be even more difficult because they require so much money needs to be taking some very careful care of the decisions that they make."

Urban and Norris were joined on the LabCentral panel by Matt McTygue, an attorney who represents venture capitalists. It's not that investors aren't doing any deals, McTygue said, but he offered a warning: "Financings that do happen during this time are going to be on more investor-favorable terms, more dilutive terms."

In other words, entrepreneurs who are desperate for funding may have to give up bigger-than-usual ownership stakes in their companies.

Read the rest here:
Biotech Firms May Be Key To Beating The Coronavirus, But They're Not Immune To Financial Worry - WBUR

Read More...

Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement – Agri-Pulse

Sunday, April 12th, 2020

The COVID-19 outbreak is gripping our planet like no other health crisis in recent history. Overt collaboration and policy action are required to meet this challenge and, as importantly, prepare for the future. Elevating and prioritizing the interconnectedness of living things through One Health strategies and modernizing Americas animal biotechnology regulatory approach are two policies Congress and the White House must confront. In fact, they are long overdue.

Sixty percent of human diseases begin in animals.Scientists are confident that the COVID outbreak originated in batsand then was spread through another animal and then to humans, like the 2002-03 SARS outbreak. As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

Aside from the dreadful health implications, the resulting economic costs of a pandemic are profound.The World Bank estimates that, between 1997 and 2009, the global costs from six zoonotic outbreaks exceeded $80 billion. While we wont know the total impact for some time, COVID-19 has already producedone of the sharpest economic downturns in U.S. history and is costing the U.S. treasury alone trillions of dollars.

Society was woefully unprepared for this pandemic. We must employ modern approaches to be ready for future outbreaks. One Health collaboration eliminates barriers that often exist between human health, animal health, and environmental health strategies to create smarter, multi-faceted and coordinated efforts.

BIO supports legislation such as the Advancing Emergency Preparedness Through One Health Act of 2019. This bill would direct the U.S. Department of Health and Human Services and the U.S. Department of Agriculture (USDA) to coordinate with other agencies and state and local leaders to advance a national One Health framework to better prevent, prepare for, and respond to zoonotic disease outbreaks like COVID-19. Congress and the White House must factor One Health into their efforts to address future pandemics.

Animal health and wellness is a critical component of One Health strategy. To help the U.S. better prepare for the future, we need changes to the U.S. animal biotechnologyregulatory system.The U.S. governments current approach to regulating animal biotechnology as a new animal drug has all but destroyed investment and blocked market access for a host of beneficial products.

Biotechnology, for example, could armpigs with resistanceto African Swine Fever. Similarly,scientists have developed achickenthat is resistant to contracting and transmitting avian influenza.

Other innovations in animal biotechnology may be able prevent, prepare for, and respond to outbreaks of infectious diseases such as coronavirus, Ebola, MERS, Zika, among others, by providing prevention strategies andtreatments for humans.

Unfortunately, the United States regulatory system for animal biotechnology is not appropriately science- or risk-based, and as a result we are falling behind other countries, such as Brazil, where innovative start-ups are finding more support.

Indeed, despite decades of animal biotechnology research and advances, only one biotech food animal has been approved to date the AquaBounty salmon which languished in the U.S. regulatory system for more than two decades and still has not hit the market because ofpolitical interference.

The current crisis underscores the urgent need to break down roadblocks to progress.

BIO is calling on the White House to direct the U.S. Food and Drug Administration (FDA) and the USDA to clarify within 30 days a plan to overhaul the current regulatory approval process for animal biotechnology.

In alettersent to the President, BIO implores the need for a new approach that 1) more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment; 2) incentivizes research and investment in the technology; and 3) ensures safe and affordable products reach consumers as soon as possible.

A joint agreement between both agencies will help farmers, innovators, and consumers realize the benefits that modern technology can bring to the United States and the world. And just may well prevent the next potential animal to human disease outbreak.

Dana OBrien,Executive Vice President,Food & AgricultureBiotechnology Innovation Organization (BIO)

The rest is here:
Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement - Agri-Pulse

Read More...

Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic – Yahoo Finance

Sunday, April 12th, 2020

MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the companys response, operationally and scientifically.

Dear Generex Shareholders,

The emergence and rapid escalation of the COVID-19 pandemic has deeply impacted our lives as we never could have imagined. During these uncertain times the health and well-being of our Generex family, including our employees, shareholders, investors and partners is paramount. For the well-being of all of our stakeholders, we are committed to following the precautions of health advisors and adhering to suggestions, advice, and laws set up by local municipalities, cities, states, and the federal government to stop this pandemic that has disrupted the world. Generex Biotechnology remains dedicated to safeguarding your investment in GNBT as we continue working towards positive outcomes into the future through our strategic initiatives and development programs, including our previously announced efforts to develop a vaccine for the SARS-CoV-2 virus.

We want to take this time to update shareholders on the steps we are taking to efficiently manage the businesses of Generex and our subsidiaries through these challenging times. We are virtually fully operational with all our business management teams and their employees through video conference and are committed to following through with our short, mid and long-term goals and plans to add value for our shareholders.

As reported Generex has jumped into the vaccine race with its Ii-Key-COVID-19 Complete Vaccine, which is designed to activate both the cellular (CD4 and CD8 T cells) and humoral (antibody) immune responses. As previously reported, we have signed an agreement with a Chinese consortium to develop our Complete Vaccine for China. Since signing the agreement, Generex has developed and refined our vaccine plans and has invoiced the Chinese consortium for the upfront payment and licensing fee.

Generex has also partnered with EpiVax, a leader in computational vaccinology, that has developed algorithms to identify specific amino acid peptide sequences or epitopes that are predicted to activate the various cellular components of the immune system including CD4 T Cells, CD8 T Cells, and B Cells that produce antibodies. An additional advantage of their vaccinology algorithms is their ability to dehumanize peptide sequences to minimize autoimmune reactions. EpiVax has identified a series of epitopes of the SARS-CoV-2 viral proteins that may be used to produce a vaccine. Generex plans to manufacture laboratory scale amounts of the EpiVax peptides linked with our Ii-Key technology to screen against blood samples from patients who have recovered from COVID-19. We are in the process of identifying hospitals and research centers that can provide us with the blood samples for peptide epitope screening. We expect this screening process to yield the best 3 to 5 Ii-Key peptides that we anticipate will make the most safe and effective vaccine for human clinical trials.

To advance our vaccine development efforts, the team at Generex has been proactive in reaching out to a number of countries, and we have had productive conversations with several government officials, Ministries of Health, and other key influencers to describe our technology, our clinical strategy, potential manufacturing partners, and our rapid path to vaccination for their populations. Generex has also met and had discussions with U.S. government agencies to provide them with details of our Ii-Key peptide vaccine technology, and we are in discussions with the decision makers for federal funding and partnership. It has been a slow process, but we believe that vaccines are now getting more government attention as local, state, and federal officials recognize the severity of this pandemic and the likelihood that the virus will return next year.

Generex has identified a clinical research organization, regulatory consultants, and clinical research sites to conduct our trials, and we are working with our contract manufacturing partners for AE37 to produce our Ii-Key-SARS-CoV-2 peptide vaccine for human clinical trials and population vaccination initiatives. We are also in discussions with pharmaceutical companies to include their vaccine adjuvants as part of the clinical trial design to evaluate the potential of using adjuvant in our vaccine formulation.

Story continues

Generex is highly confident in our rapid vaccine development program and in our plans to scale the manufacturing of Ii-Key- SARS-CoV-2 peptide vaccines to conduct not only the clinical trials required to meet the approval standards of global regulatory authorities, but to meet government expectations for mass population vaccination.

In conclusion, while the COVID-19 pandemic is surely a fast evolving situation with multiple layers of complexity, we believe market conditions should ultimately favor long-term minded, value oriented, and fundamental investors. Generex has many subsidiaries and many assets, from its FDA-cleared wound care product Excellegen, to our development products in inflammatory bowel diseases, diabetes, infectious disease, and cancer, to our pending operations in Arizona, with the ultimate vision of building a HMO with, in our opinion, unprecedented benefit packages through our own products, devices, and ancillary services. Based on all these efforts and assets, it is my belief that Generex has the staying power to thrive and bring value to our shareholders. Rest assured, Generex is well equipped to navigate the current environment as we remain focused on our core competencies and businesses while positioning our high-value assets for the future.

In the immediate days ahead, we will continue working to solidify the development path and government partnerships to complete our Ii-Key-SARS-CoV-2 Complete Vaccine program so that we can make a difference not only for Generex, our employees, and our shareholders, but for the world. Finally, we thank you all for your continued support as we navigate through this difficult period together, and please everyone, stay safe, be well and take care of your families and friends.

Sincerely,Joe MoscatoCEO

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

See the original post:
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic - Yahoo Finance

Read More...

Anti-Covid consortium in India working on therapeutic antibodies – India New England

Sunday, April 12th, 2020

New DelhiAn anti-Covid consortium of experts with the assistance of Department of Biotechnology is working towards producing therapeutic antibodies against Covid-19.

In India, one such effort is being led by Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology.

Chaudharys group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection.

These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes.

This work is being undertaken as part of an Anti-Covid consortium under the leadership of Chaudhary and involving Amulya Panda at National Institute of Immunology and Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).

Covid 19 is caused by the novel SARS coronavirus-2 (SARS-CoV-2) and it is resulting in many deaths. However, a large number of infected people are also recovering despite not having any specific treatment. This is because of antibodies produced within the body in response to the virus invasion.

Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for treatment of numerous disease conditions such as diphtheria, tetanus, rabies and ebola.

Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2, a statement by Department of Biotechnology said. (IANS)

See original here:
Anti-Covid consortium in India working on therapeutic antibodies - India New England

Read More...

(2020-2025) Agriculture Biotechnology Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers…

Sunday, April 12th, 2020

Latest Report onAgriculture Biotechnology Market

The report titled Global Agriculture Biotechnology Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Agriculture Biotechnology market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Agriculture Biotechnology market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Agriculture Biotechnology market is carefully analyzed and researched about by the market analysts.

Agriculture Biotechnology Market competition by top manufacturers/ Key player Profiled: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences

Request a sample copy of the report with Detail TOC and List of Figures @ https://www.alexareports.com/report-sample/692707

Global Agriculture Biotechnology Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2024. According to the latest report added to the online repository of Alexareports the Agriculture Biotechnology market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2024.

Agriculture Biotechnology Market Segment by Type covers: Biochips, Deoxy ribonucleic acid (DNS) sequencing, Genome editing tools, Ribonucleic acid interference (RNAI), Synthetic biology

Agriculture Biotechnology Market Segment by Application covers:Transgenic crops market, Synthetic biology-enabled products market

After reading the Agriculture Biotechnology market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Agriculture Biotechnology market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalAgriculture Biotechnology market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Agriculture Biotechnology market?What are the key factors driving the global Agriculture Biotechnology market size?Who are the key manufacturers in Agriculture Biotechnology market space?What are the market opportunities, market risk and market overview of the Agriculture Biotechnology market?What are sales, revenue, and price analysis of top manufacturers of Agriculture Biotechnology market?Who are the distributors, traders, and dealers of Agriculture Biotechnology market?What are the Agriculture Biotechnology market opportunities and threats faced by the vendors in the global Agriculture Biotechnology industries?What are sales, revenue, and price analysis by types and applications of Agriculture Biotechnology market?What are sales, revenue, and price analysis by regions of Agriculture Biotechnology industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/692707

Some of the Major Highlights of TOC covers:

Agriculture Biotechnology Regional Market Analysis

Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Revenue by RegionsAgriculture Biotechnology Consumption by RegionsAgriculture Biotechnology Segment Market Analysis (by Type)

Global Agriculture Biotechnology Production by TypeGlobal Agriculture Biotechnology Revenue by TypeAgriculture Biotechnology Price by TypeAgriculture Biotechnology Segment Market Analysis (by Application)

Global Agriculture Biotechnology Consumption by ApplicationGlobal Agriculture Biotechnology Consumption Market Share by Application (2014-2020)Agriculture Biotechnology Major Manufacturers Analysis

Agriculture Biotechnology Production Sites and Area ServedProduct Introduction, Application and SpecificationAgriculture Biotechnology Production, Revenue, Ex-factory Price and Gross Margin (2014-2020)Main Business and Markets Served

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/692707

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

See the rest here:
(2020-2025) Agriculture Biotechnology Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers...

Read More...

Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? – Yahoo Finance

Sunday, April 12th, 2020

Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The US$283m market-cap company announced a latest loss of -US$75.6m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on PBYIs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for PBYIs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Puma Biotechnology

PBYI is bordering on breakeven, according to the 8 Biotechs analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$11m in 2022. So, PBYI is predicted to breakeven approximately 2 years from now. What rate will PBYI have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 62%, which is extremely buoyant. If this rate turns out to be too aggressive, PBYI may become profitable much later than analysts predict.

NasdaqGS:PBYI Past and Future Earnings April 8th 2020

Underlying developments driving PBYIs growth isnt the focus of this broad overview, however, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing I would like to bring into light with PBYI is its debt-to-equity ratio of over 2x. Typically, debt shouldnt exceed 40% of your equity, which in PBYIs case, it has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are too many aspects of PBYI to cover in one brief article, but the key fundamentals for the company can all be found in one place PBYIs company page on Simply Wall St. Ive also put together a list of key aspects you should further research:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Follow this link:
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? - Yahoo Finance

Read More...

This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low – The InvestChronicle

Sunday, April 12th, 2020

For the readers interested in the stock health of Vir Biotechnology, Inc. (VIR). It is currently valued at $33.19. When the transactions were called off in the previous session, Stock hit the highs of $38.74, after setting-off with the price of $36.5. Companys stock value dipped to $32.15 during the trading on the day. When the trading was stopped its value was $29.00.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -55.74% during the 52-week period from high price, and 184.91% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 130.62%, having the revenues showcasing 140.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.21B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.19, with a change in the price was noted +19.48. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +146.80% for the period of last 100 days, recording 572,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 28.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.94%. In the last 20 days, the companys Stochastic %K was 11.97% and its Stochastic %D was recorded 11.37%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 130.62%. The shares increased approximately by 1.54% in the 7-day charts and went up by -15.45% in the period of the last 30 days. Common stock shares were driven by 140.86% during last recorded quarter.

Here is the original post:
This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low - The InvestChronicle

Read More...

FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19 – BioSpace

Sunday, April 12th, 2020

EIDD-2801, an oral broad-spectrum antiviral proceeding into Clinical Trials

ATLANTA and MIAMI, April 6, 2020 /PRNewswire/ -- Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application by Drug Innovation Ventures at Emory (DRIVE), LLC, wholly owned by Emory University, for an orally available antiviral compound, EIDD-2801, exclusively licensed to Ridgeback Biotherapeutics, LP (Ridgeback), a closely held biotechnology company. This action by the FDA allows Ridgeback to initiate human clinical testing of EIDD-2801 in the United States.

"We are thankful to FDA Commissioner Dr. Steven Hahn and his team at the Anti-Viral Division for the unprecedented speed in reviewing our submission, the guidance and the highly collaborative process that ensures this promising drug can advance into the clinical development as fast as possible," said Wendy Holman, Chief Executive Officer of Ridgeback. "We also appreciate the guidance we have received from the Assistant Secretary of Preparedness and Response (ASPR), including discussions that occurred months before COVID-19 first emerged, to help Emory/DRIVE advance the development of EIDD-2801 as quickly as possible to address this global pandemic."

EIDD-2801 prevents the replication of SARS-CoV-2, the virus that causes COVID-19, and has shown potent activity against SARS-CoV and MERS-CoV in animal models of infection. In addition to coronaviruses, EIDD-2801 has broad spectrum activity against a number of diseases of public health concern, including influenza, chikungunya, Ebola, and equine encephalitis (VEE and EEE). The antiviral is orally available and, in addition to COVID-19, is being developed for the treatment of seasonal and pandemic influenza under a contract awarded to Emory Institute for Drug Development by the National Institute of Allergy and Infectious Diseases (NIAID) and for Venezuelan and Eastern equine encephalitis virus (VEEV and EEEV) by the Defense Threat Reduction Agency (DTRA).

"FDA's prompt approval of our IND allows us to initiate human testing for EIDD-2801 as quickly as possible," says George Painter, Ph.D., director of the Emory Institute for Drug Development (EIDD) and CEO of DRIVE. "We are grateful to our collaborators for helping us to assemble this application quickly, and to the FDA for expediting the process. An orally available antiviral medication would be a critical weapon for fighting COVID-19."

Ridgeback and DRIVE have established a partnership to advance EIDD-2801 through clinical development and to optimize availability during the current COVID-19 pandemic. EIDD-2801 was exclusively licensed to Ridgeback in March 2020.

"We look forward to our continued work with the highly experienced drug development team at DRIVE and the dedicated medical, public health and governmental personnel who are on the frontlines of this pandemic in the United States and abroad," says Wendy Holman, CEO of Ridgeback Biotherapeutics. "The ability to deliver promising treatments to patients in need is what makes us excited to come to work every day. Ridgeback brings its unique perspective, honed by our success developing an Ebola therapeutic during the 2018-2020 outbreak in the DR Congo, to help advance EIDD-2801 for the treatment of diseases that are critical to pandemics and global health."

About EIDD-2801:

EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. In animal studies of two distinct coronaviruses (SARS-CoV1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. The development of EIDD-2801 has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), under contract numbers HHSN272201500008C and 75N93019C00058, and from the Defense Threat Reduction Agency (DTRA), under contract numbers HDTRA1-13-C-0072 and HDTRA1-15-C-0075.

About Ridgeback Biotherapeutics LP:

Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company focused on orphan and infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions. Ridgeback is in the process of completing a Biologics Licensing Application with the Food & Drug Administration for mAb114 (ansuvimab) for the treatment of Ebola. Ansuvimab development has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00059 and 75A50120C0009.

About DRIVE:

DRIVE is a non-profit LLC wholly owned by Emory University and started as an innovative approach to drug development. Operating like an early stage biotechnology company, DRIVE applies focus and industry development expertise to efficiently translate discoveries to address viruses of global concern. DRIVE's mission is to discover and develop antiviral drugs for emerging infections, pandemic threats, and biodefense (e.g. COVID-19, swine flu, bird flu, dengue, chikungunya, Ebola, Zika, and viral encephalitis). Because these diseases are major threats, antiviral drugs are critically needed to treat them; however, they are generally not profitable enough for industry to pursue, and thus are considered neglected diseases. DRIVE is unique in that it brings industry expertise to the assets of a leading research University to develop potential antiviral drugs to a de-risked value inflection point that substantially increases the probability of the potential drug being licensed by industry and developed for the ultimate benefit of the public. DRIVE's executive team, led by George Painter, has over three decades of drug development experience within both large pharmaceutical and biotechnology companies, including leading the development of multiple FDA approved antivirals to treat HIV and Influenza, among other viral diseases, including AZT and Relenza.

About Defense Threat Reduction Agency:

The Defense Threat Reduction Agency (DTRA) was formally established on October 1, 1998. DTRA enables the Department of Defense, the United States Government and International partners to counter and deter weapons of mass destruction and improvised threat networks. As a Combat Support Agency and a Defense Agency, DTRA's mission is to counter the threats posed by the full spectrum of weapons of mass destruction (WMD), including chemical, biological, radiological, nuclear, and high-yield explosives; counter the threats posed by the growing, evolving categories of improvised threats, including improvised explosive devices, car bombs and weaponized consumer drones, as well as the tactics, technologies and networks that put them on the battlefield; and ensure the U.S. military maintains a safe, secure, effective and credible nuclear weapons deterrent.

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

SOURCE Ridgeback Biotherapeutics LP

See the rest here:
FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19 - BioSpace

Read More...

Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board – Business Wire

Sunday, April 12th, 2020

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported Timothy P. Walbert, Chairman, President and CEO of Horizon Therapeutics plc, will succeed Chad Mirkin, Ph.D. as Chairman of Exicures Board of Directors. Dr. Mirkin, who will remain on the Board, is stepping down as Chairman due to his responsibilities at Northwestern University, where he is Professor and Director of the International Institute for Nanotechnology.

Tim Walbert has served as the president and chief executive officer of Horizon Therapeutics since 2008 and has served as chairman of its board of directors since 2010. Prior to joining Horizon, he served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company acquired by Takeda America Holdings, Inc. in 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biotechnology company. Mr. Walbert was also divisional vice president and general manager of immunology, where he led the global development and launch of the multi-indication biologic HUMIRA at Abbott, now AbbVie. Tim received his Bachelor of Arts in Business from Muhlenberg College, in Allentown, PA. He serves as chairman of the board of Zyla Life Sciences, co-chairman of the board of MATTER and serves on the board of the Illinois Biotechnology Innovation Organization (iBIO), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. He is a member of the Illinois Innovation Council, the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College.

Exicure is poised to change pharmaceutical development by opening up the field of digital medicine with its proprietary spherical nucleic acid (SNA) technology. Exicures existing programs and pipeline are promising, and the Company has many untapped therapeutic areas yet to be tackled. I look forward to working with the Exicure team to advance the Companys current clinical programs and take the Company into its next stage of development, while continuing to build its pipeline of new therapeutic candidates, said Mr. Walbert.

It has been a pleasure to serve as Chairman since we founded the company in 2011 and to help guide Exicure, said Dr. Mirkin. We have created a clinically-focused company with growing opportunities in neurology and an asset in immuno-oncology that is looking promising in clinical trials for several indications. The platform and team are strong and the potential opportunities are significant. As we continue to execute on our strategy and bring candidates through the clinic into commercialization, Tims experience and leadership in this area will be extremely valuable.

Under Chads leadership, we built a leading platform company focused on developing therapeutics based on our technology, initiated a clinical program (XCUR-FRN) in Friedreichs ataxia, advanced our immuno-oncology candidate AST-008 into Phase 2 clinical trials, entered into an exciting partnership with Allergan in hair loss disorders and finished 2019 with $110 million of cash on hand, said Dr. David Giljohann, Chief Executive Officer of Exicure. I am looking forward to Tims leadership as we continue to grow Exicure, concluded Dr. Giljohann.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNAbased therapeutic candidate, for the treatment of Friedreichs ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and also has an office in Cambridge, MA.

For more information, visit Exicures website at http://www.exicuretx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact could be deemed forward looking including, but not limited to, statements about the companys business strategy and plans, including its leadership in the field of digital medicine and development of product candidates based on its proprietary SNA technology and the companys transition from the clinic to commercialization; the advancement of the companys pipeline and product candidates; the potential of the companys collaborations and R&D efforts; and anticipated market opportunities for the companys product candidates in neurology and in immuno-oncology. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on managements current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risks that the COVID-19 pandemic may disrupt the companys business and/or the global healthcare system more severely than anticipated, which may have the effect of further delaying our ability to enroll and complete the companys ongoing Phase 1b/2 clinical trial, unexpected costs, charges or expenses that reduce cash runway; that the companys pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments and the ability of Exicure to protect its intellectual property rights. Furthermore, data from preclinical studies often fails to be indicative of outcomes in human trials. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Exicure undertakes no duty to update this information, except as required by law.

Continue reading here:
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board - Business Wire

Read More...

Molecular Weight Marker Market Opportunities, Challenges, Growth, Revenue and Forecast 2015 to 2021 – Daily Science

Sunday, April 12th, 2020

Molecular weight markers are used to calculate sample molecular weights in the medical research arena. In addition, these markers play a vital role in the monitoring of the progress of an electrophoretic run in separation and analysis of macromolecules. Molecular weight markers include RNA, DNA, and protein markers.

The global molecular weight market is categorized on the basis of applications, products, end users, and staining procedures. Based on the type of applications, the report comprises protein and nucleic acid applications. The protein application segment is further subsegmented into gel extraction and Western blotting applications. Protein application is the fastest-growing segment in the molecular weight marker market. Nucleic acid applications include polymerase chain reaction (PCR), Northern blot, sequencing, molecular cloning, and Southern blot. The nucleic acid segment holds the largest market share in the global molecular weight marker market.

Request to Sample report @ https://www.persistencemarketresearch.com/samples/4385

On the basis of product, the report covers protein and RNA and DNA markers. These products are categorized on the basis of their marker sizes. The protein and RNA markers sizes included in the report are below 10 kilo Dalton (kDa), 10 kDa to 100 kDa, 100 kDa to 200 kDa, and above 200 kDa markers. The DNA markers sizes included in the report are below 50 base pair (bp), 50 bp to 100 bp, 100 bp to 1 kilo base pair (kb), 1 kb to 5 kb, and above 5 kb.

On the basis of end user, the global molecular weight marker market report is segmented into biotechnology and pharmaceutical companies, academic research institutes, and contract research organizations. The staining segment is further subsegmented into unstained, prestained, and specialty markers.

Request PMR insights on measuring the impact of COVID-19 coronavirus across industries.

In terms of geography, North America dominates the global molecular weight marker market. This is due to increased awareness about therapeutic applications of molecular biomarkers in disease management in the region. In addition, improved life science infrastructure has also propelled the growth of the molecular weight marker market in the region. The U.S. represents the largest market for molecular weight markers in North America, followed by Canada. In Europe, Germany, France, and the U.K. hold major shares of the molecular weight marker market. The molecular weight marker market in Asia too, is expected to show high growth rates in the next five years. This is due to the proliferation of biotechnology companies setting up manufacturing facilities in the region. Moreover, the growing life science infrastructure is also driving the growth of the market in the region. India, China, and Japan are expected to be the fastest-growing markets for molecular weight markers in Asia.

Request to View TOC @ https://www.persistencemarketresearch.com/toc/4385

The increasing prevalence of chronic diseases that require molecular biomarkers for their treatment is a key driver of the global molecular weight marker market. In addition, increasing government supports in the form of funding in the life science arena is also supporting the growth of the global molecular weight marker market. Increasing investment in R&D in biotechnology and pharmaceutical sectors and innovative applications of molecular weight markers have fueled the growth of this market. However, lack of skilled healthcare professionals obstructs the growth of the global molecular weight marker market.

Increasing numbers of mergers and acquisitions between biotechnology and pharmaceutical companies is a key trend of the global molecular weight marker market.

The major companies operating in this market are ,

For in-depth competitive analysis, buy [emailprotected] https://www.persistencemarketresearch.com/checkout/4385

See more here:
Molecular Weight Marker Market Opportunities, Challenges, Growth, Revenue and Forecast 2015 to 2021 - Daily Science

Read More...

Aging is a mixed picture – Great Bend Tribune

Sunday, April 12th, 2020

During my lifelong practice of geriatrics, I observed many people reaching the end of their lives. Truth is, what Ive seen is a mixed picture. The two patient stories I describe here are really a blend of hundreds of experiences.

Ms. A is in her late 80s, walks two miles every day, mostly outside but inside a wellness center when sidewalks are icy. She eats a balanced light diet and is connected to many friends. Ms. A is spiritually connected, and life has been and continues to be meaningful to her.

Ms. B is also in her late 80s, has never been much for exercise and now is unable to walk without the help of her walker. She lives in an assisted living center and has made some friends there but remains rather critical of them. Whenever her kids visit, she asks them to take her home. Ms. B had some tough times and some happy times during her life, but now, she remains rather bitter.

At age 82, comedian Rodney Dangerfield, who had studied the relationship between sexuality and longevity said, Im at the age where food has taken the place of sex in my life. In fact, Ive just had a mirror put over my kitchen table. Reading that made me laugh out loud, but I see Dangerfields comment as both funny and sad. Indeed, this thing called growing old is a mixed picture. Should we celebrate it or fear it? Does it give wisdom and meaning or just aches and pains?

I suggest we embrace both sides of the picture. Lets choose to live as long and as well as our luck and genetics allows. We would all do better with regular exercise, eating less, connecting with both the earthly and the spiritual. Lets also choose to kindly accept the fact that someday we will reach the end of our lives. We can take healthy steps by creating an advanced directive, by understanding the kinds and causes of dementia and facing the inevitable death of the ones we love. Embracing this mixed picture helps us in accepting aging processes we cannot change, avoiding suffering and savoring things that matter.

Bottom line lessons from Ms. A and B: Like any piece of art, we can choose how we view the picture of our own aging. Those who live with misery, anger and vengefulness will likely die that way. Those who glean meaning and joy from observation, giving to others and opening their hearts to the spiritual will find aging a grand masterpiece.

Richard P. Holm, MD passed away in March 2020 after a battle with pancreatic cancer. He is founder of The Prairie Doc. For free and easy access to the entire Prairie Doc

Read the original here:
Aging is a mixed picture - Great Bend Tribune

Read More...

Adrenomyeloneuropathy Treatment Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2025 – Science In Me

Sunday, April 12th, 2020

The Adrenomyeloneuropathy Treatment Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Adrenomyeloneuropathy Treatment market reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands. Adrenomyeloneuropathy Treatment market reports provides all data with easily digestible information to guide every businessmans future innovation and move business forward.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28645

The worldwide Adrenomyeloneuropathy Treatment market is an enlarging field for top market players,

key players and government is expected to spur the adrenomyeloneuropathy treatment market.

The North America market for adrenomyeloneuropathy treatment is expected to retain its dominance, owing to increasing patient pool for rare disease, increasing government funding to accelerate the research and development for rare disease. According to Genetic and Rare Diseases Information Center, more than 25 million Americans are suffering from rare disease in United States.Europe is expected to account for the second largest share in the global adrenomyeloneuropathy treatment market owing to growing clinical trial funding programs for orphan drug development and high prevalence of adrenomyeloneuropathy and high treatment seeking rate. Asia Pacific is expected to show significant growth, owing to increasing diagnosis rate and improvement in healthcare infrastructure. China is expected to show significant growth in the adrenomyeloneuropathy treatment market, due to rising population improving R&D capability, increasing per capita heath spending. Latin America and Middle East & Africa is expected to show growth owing to lack of diagnosis and inadequate healthcare facilities and lack of skilled physicians for Adrenomyeloneuropathy Treatment market.

Examples of some of the key manufacturer present in the global adrenomyeloneuropathy treatment market are Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics among others.

The report covers exhaustive analysis on,

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28645

This Adrenomyeloneuropathy Treatment report begins with a basic overview of the market. The analysis highlights the opportunity and Adrenomyeloneuropathy Treatment industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Adrenomyeloneuropathy Treatment insight regarding the things which are driving and affecting the earnings of the market. The Adrenomyeloneuropathy Treatment report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28645

Research objectives and Reason to procure this report:-

Finally, the global Adrenomyeloneuropathy Treatment market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Adrenomyeloneuropathy Treatment industry is a source of means and guidance for organizations and individuals interested in their market earnings.

The rest is here:
Adrenomyeloneuropathy Treatment Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2025 - Science In Me

Read More...

What Is Time Blindness and Do You Have It? – The Cut

Sunday, April 12th, 2020

Photo: Getty Images/Image Source

Im not in therapy right now, but my twin sister is, and sometimes I ask her for insights. Your twin should be able to be your therapy plus-one, I say. The other day, she missed an appointment for no discernible reason. She had been doing some law school work on her computer, making lunch, just puttering around, and she looked at the time and her session had passed. My therapist said it was time blindness, she told me later. Were all time blind. I thought, Oh yes, thats right. Time blind, just like being unable to distinguish between red or blue.

Im self-isolating 3,000 miles away from my twin, who is staying with our parents in Southern California. Im in New York. We FaceTime every day, but I havent seen her in person since Christmas. I know how much time has officially passed. A whole season: the last time I hugged her I wore a big winter coat. But it feels much longer, like we unknowingly entered into a new century since then, another era. When I finally see her again we will speak a different language than the one we used to. Maybe we wont even look like each other any more. Other times I swear I heard her laugh just the other day.

Time blindness is a term coined by doctors who treat people with attention deficit hyperactivity disorder. Dr. Ari Tuckman, a Pennsylvania-based psychologist who specializes in ADHD, said adults typically develop an innate awareness of time and an ability to track its passing. Some people have what he calls a harder, or sharper time awareness: they know when theyve been out for lunch too long, or when something hasnt been in the oven for long enough. Others have a much softer one; they can miss appointments and trains, or play a game for hours and not realize they havent eaten dinner. At the severe end of the spectrum, toward the soft end, is time blindness, which can profoundly impact someones life, if they cant ever keep deadlines or make social events. People with ADHD are often more time-blind than others.

On top of our individual time awareness, Tuckman says, context plays a role: Sleep deprivation, anxiety, depression, being drunk, anything that might impact how we process the world, can make us feel more time-blind. And context has wildly changed for us all at this moment in history, he says. Without the usual time-marker cues we might use to divide up our days the school bus arriving, standing on a crowded train platform, the line at the coffee shop, weekend nights spent at restaurants with friends were swimming in a sea of sameness. Its like driving through a haze where theyre just not as many distinct landmarks, he tells me. Even if before all this, you mightve called yourself a stickler for time, youre likely having a hard time sticking. Youre throwing darts into a viscous, slippery time jelly.

Grief is one of the biggest causes oftime blindness, according to Tuckman. What am I mourning? People who are gone. Places I used to go. Seeing my sisters face, for real. Holding onto time is a skill of your mind, like doing math, and sadness sucks up its computing strength. Its why time goes faster when I talk to her, when Im not so sad, even though I want it to feel longer.

Tuckman said it might be nice for more people to understand time blindness, if only to help normalize this feeling that clocks have stopped working, or theyve stopped being applicable to our lives. Trains and appointments were our context clues, yes, but so were other people. He says talking to them, even while physically apart, can be a way to keep time. Loved ones are good clocks.

Get the Cut newsletter delivered daily

More:
What Is Time Blindness and Do You Have It? - The Cut

Read More...

‘Blindness is on its way’: Amitabh Bachchan blogs about losing vision – Indulgexpress

Sunday, April 12th, 2020

Amitabh Bachchan

Bollywood veteran Amitabh Bachchan has expressed concern over the condition of his vision. The veteran actor is afraid that he might just turn blind.

"The eyes they see blurred images .. the vision reads double and for some days now I reconciled myself to the fact that blindness is on its way, to add to the million other medical problems that invest in me," expressing his concern, Amitabh Bachchan wrote on his blog.

The actor also went down the memory lane to recall how his mother would cure him if he ever got hurt in the eyes. "But then .. today .. thought of those early years when Ma used to take the edge of the sari, the pallu' , make a soft round ball with it , blow into it to make it warm and place it on the eye .. and BAM ! problem solved ..So followed that .. hot watered a hand towel and placed it on the eyes," he wrote.

Big B later revealed that his doctor has assured him that he is not turning blind. It is just enhanced screen-time which is taking a toll on the eye. "spoke to the doc and followed his instruction of putting in prescribed eye drops every hour .. reassured me that I was not going blind - that there was far too much time being spent in front of the computer .. the eyes were tired .. thats all."

However, Bachchan sounds happy that following his mother's homely remedy has worked wonder on his eyes! He expressed: "And YES .. that old Mother's technology worked .. YEEAAHHH .. I can see now!!"

Read the original post:
'Blindness is on its way': Amitabh Bachchan blogs about losing vision - Indulgexpress

Read More...

Reading in the time of coronavirus – Salisbury Post – Salisbury Post

Sunday, April 12th, 2020

By Hannah Hemphill

Rowan Public Library

For me, there is something eerie but also comforting about reading dystopian fiction during a time of isolation and quarantine. As the reality of coronavirus comes to Rowan County, I have a few suggestions for titles that can help us put the effects of this virus on our community into perspective.

Check out the following titles to read in self-isolation. All of them are available through the NC Digital Library, which is free to use with your Rowan Public Library card. Dont have a card? Fill out an application for a Digital Library Card through our website, http://www.rowanpubliclibrary.org.

Students at a small college start to fall asleep and not wake up in Karen Thompson Walkers The Dreamers. This mysterious sleeping illness then starts to spread to the town. Many elements of this novel will feel eerily familiar as cases multiply, classes are canceled, and quarantines are established.

The fantastical nature of Peng Shepherds debut novel, The Book of M, adds to the feeling of strangeness that we are all experiencing in our daily lives. The Forgetting is spreading like the plague, causing chaos and disaster for the world. Follow Ory as he tries to find his wife, Max, before she forgets everything, including him.

If youre looking for a more serious dystopian feel, try Blindness, a classic by Portuguese author Jose Saramago. The world is hit by an outbreak of white blindness. Those afflicted are quarantined by the government to try to prevent the spread, subjected to a criminal element that develops, and witness the disintegration of society as a whole. Follow through the eyes of the only person who can see, witnessing the good, the bad and the ugly in humanity.

Finally, for those who want to flaunt social distancing policies, try The Salt Line by Holly Goddard Jones. Set in the more familiar setting of mountainous North Carolina, follow along with a group of adrenaline junkies who pay to jump the salt line, a protective measure put in place against a deadly tick-borne illness. Things do not go as planned for the group as they become hostages of Ruby City; a group of outer-zone survivors.

Honorable Mentions

The following titles are also available through the NC Digital Library but have more considerable wait times. Place a hold today!

Severance Ling Ma

Love in the Time of Cholera Gabriel Garca Mrquez

I Am Legend and Other Stories Richard Matheson

The Maze Runner series James Dashner

See the article here:
Reading in the time of coronavirus - Salisbury Post - Salisbury Post

Read More...

Amitabh Bachchan expresses concern about fading vision, says blindness is on its way – Republic World – Republic World

Sunday, April 12th, 2020

Bollywood's megastar Amitabh Bachchan who is known to impress fans with his metal, expressed his deep concern over his fading vision and also his apprehensions over the fact that he is turning blind.While extending out his best wishes to all his fans across on Good Friday on his blog, the actor shared his picture and expressed the concern of blurred images and losing sight.

Read:Amitabh Bachchans Adorable Throwback Posts On Instagram That Are A Must-see For Every Fan

Read:Aamir Khan Dislikes An Iconic Movie Starring Amitabh Bachchan And Hrithik; Read To Know

In the blog, the actor who has a contribution to the Hindi film fraternity fordecades wrote that his eyes have started seeing blurred images, the vision reads double and for some days now he has realized that "blindness is on its way". He also wrote that this disease will pile on as other diseases have in his body. Apart from this, the actor even took a trip down the memory lane and recapitulated all the old faded memories of how his mother, Teji Bachchan would cure him if he ever got hurt in the eyes. He remembered how his mother would make softballs of sari's pallu and then used to blew air and place it on his eye. And guess what, the problem used to vanish like anything.

The 'Piku' star then explained how after consulting his doctor, he got reassured that probably he is not getting blind and its the result of the extra screen which is straining his eyes. He tried the new age remedy like a hot water hand towel and placed it on the eyes. He consulted an eye specialist and followed his instructions of putting in prescribed eye drops every hour which reassured him that he is not getting blind anymore.

Read:Amitabh Bachchan's Memorable Movies From The 90s; 'Agneepath' To 'Sooryavansham'

Read:Amitabh Bachchan Can Graciously Pull Off The Casual Look And These Pictures Are A Proof

A day earlier the veteran star extended his best wishes to his beloved actor turned politician wife Jaya Bachchan on her birthday on his blog. The actor informed his fans that this time the couple could not be together on this special day as Jaya was in Delhi at Parliament when the lockdown happened and got stuck in the capital and could not come back home. He assured his fans that the actor is safe and in good health.

Get the latest entertainment news from India & around the world. Now follow your favourite television celebs and telly updates. Republic World is your one-stop destination for trending Bollywood news. Tune in today to stay updated with all the latest news and headlines from the world of entertainment.

Follow this link:
Amitabh Bachchan expresses concern about fading vision, says blindness is on its way - Republic World - Republic World

Read More...

Coronavirus and the Blindness of Authoritarianism: A country hiding the tragedy of Coronavirus – World-Wire

Sunday, April 12th, 2020

Coronavirus and the Blindness of Authoritarianism: On March 20, people are celebrating the new year Navroz of the Pharisees. On the other hand, there are serious apprehensions that the government of Iran is engaged in efforts to suppress the spread and impact of the virus in a big way.

It is also feared that the situation here may worsen in the coming time. Since the onset of the coronavirus havoc in the country, Mohammed has been continuously making every effort to save the lives of his patients without resting.

Mohammed is a doctor in a hospital in Irans northern province of Gilan. He has not met his family even once in the last 14 days. They have lost their associates. He has lost his friends, including one of his former counselors who was his teacher in medical school. He recently succumbed to the Coronavirus.

According to Mohammed, It is not only about our hospital. Corona has disabled our entire health system. He says, Staff morale has fallen. Our families are very worried and we are under tremendous pressure.

We are not giving the real name of Mohammad here because speaking against the government in Iran can demonstrate challenging. You can be arrested for doing so.

But, many doctors from every part of the northern province of the country have given shocking information to the BBC about this difficult situation. They have told how bad conditions they are facing and how the government has failed to handle this crisis.

Mohammed said, We do not have a sufficient number of masks. Everyday deaths are happening in our medical staff. He said, I do not know how many deaths have occurred, but the government is busy suppressing the reality of this tragedy. They lied within days of the onset of the disease.

On the other hand, 16 countries claim that the disease has spread from Iran to them. These countries are Iraq, Afghanistan, Bahrain, Kuwait, Oman, Lebanon, United Arab Emirates, Canada, Pakistan, Georgia, Estonia, New Zealand, Belarus, Azerbaijan, Qatar and Armenia.

Those who criticize the government say that the government of Iran is continuously presenting this crisis by reducing it. In its first announcement on February 19, the government said that people should not panic. The countrys Supreme Leader Ayatollah Ali Khamenei accused Irans enemies that they are showing this danger by exaggerating.

After a week, the number of cases and deaths increased. President Hassan Ruhani reiterated the words of the countrys Supreme Leader and warned against conspiracies and attempts to intimidate the enemies of the country.

He said that the aim of these conspiracies is to derail the country. He called upon the people of Iran to continue their daily life and go to work. Recently, government-controlled TV programs announced that the coronavirus could be a US-made biological weapon. The Supreme Leader tweeted about a biological attack.

According to the Iranian Health Ministry, as of 19 March, there were 17,361 cases of COVID-19 in the country, while the death toll from it stood at 1,135.

Iran is at number three after China and Italy in the worst cases of the virus. Doctors in the three most affected provinces in Iran Gilan, Golestan, and Mazandaran in Iran told the BBC that the number of test kits for coronavirus is low and that medical supplies are limited.

These include common medications, oxygen tanks, sterilized masks, protective scrubs, and gloves. The doctors now have to work in the Temporary field hospitals.

An intensive care doctor described how the hospital at his local football stadium was built and beds were built to handle the ever-increasing number of patients.

All the doctors whom the BBC spoke to said that based on their experience they can say that the government statistics related to this disease are very low compared to reality.

A doctor from Golestan province said that on an average 300 patients are visiting his hospital every day. They estimate that 6070 percent of these patients suffer from the coronavirus.

He said that due to a lack of resources, only critically ill patients are admitted and only those who are being admitted are being counted in the government figures.

The doctor told that on an average of 5 patients are dying in their homes every day for the past two weeks. They say that often by the time someone comes with a coronavirus testing kit, their patient is dead.

The most painful thing for medical staff is to lose loved ones. Medical professionals say that they have lost many of their colleagues so far. A very sad case came at the end of February of 25-year-old Nazis Khanalizadeh.

She was a nurse in the northern city of Lahijan, Iran. His photo went viral on social media. However, the government refused to believe that he died of COVID-19.

Government-controlled TV channels are constantly presenting a picture of medical staff showing them as fearless and fighting at the forefront fighting against the virus with courage and saving patients lives. Used to be.

However, soon after Nazis death, the Iranian Nursing Organization confirmed that she had died of the coronavirus.

How did the virus spread so fast?According to the government, it started with two patient zero (ie the first patient who is the carrier of an infectious disease and beyond which this infection spreads).

Both these patients died on 19 February in the city of Qom, Iran. According to the government, one of these patients came in contact with the virus in China.

The population quickly became the center of this transition in Iran. The city is a major shrine for Shia Muslims. The top Islamic religious leaders live here. Every year about 2 crore domestic and about 25 lakh foreign tourists come to this city.

Thousands of pilgrims roam the city every week. They visit the shrines and prominent places here and pay their respects by kissing and touching them.

The virus spread rapidly and cases started to grow. However, instead of swiftly quarantining the city, representatives of the Supreme Leader, such as Maulvi Muhammad Saeedi, campaigned that pilgrims continue to visit the city.

He had said, We believe that disease is cured in the holy religious place, so people should come here and be free from spiritual and physical diseases.

Richard Brennan, director of emergency operations of the World Health Organization (WHO), said, KOM is religiously special and because of this, the movement of domestic and foreign tourists from Iran continued. Due to this the virus spread quickly throughout the whole country.

Brennan has just returned from KOM recently. He said that during his visit, he has seen efforts to increase functioning in the testing labs and hospitals in KOM and the capital Tehran.

The religious places of the city have now been closed.Did the government try to hide it?In February, two major events in the country the 41st anniversary of the Islamic Revolution were celebrated and parliamentary elections were held. On February 11, several days before the victory of the Islamic Revolution, I and my colleagues recorded an unusual respiratory disease for the first time, said a senior doctor. He said that he sent several reports from his hospital to Tehran to the Senior Health Ministers warning about the onset of the virus.

We believe that the health authorities have decided to hide the fact that the coronavirus has reached Iran so that they can continue with normal state-sponsored programs, he said.

The anniversary of the revolution and the electoral platform was considered a test of the popularity of the government, as the past six months have not been very good for the Iranian people.

In November 2019, there were violent protests against the rise in oil prices. Besides, in retaliation after the death of top Iranian commander Qasim Sulemani in the US attack, Iran attacked the US military base in Iraq with missiles. Due to this, tension reached its peak in America and Iran.

The fall of Ukraines passenger plane in Iran cost 176 lives. Initially Iranian officials denied that the plane was shot down by a missile, but later this mistake was accepted. Due to this, peoples trust in the government was shaken.

Irans supreme leader, Ayatollah Ali Khamenei, has accused Irans enemies of increasing the threat of the Coronavirus so that voters can stay out of the elections.

Khamenei said, The negative propaganda was going on for several months. And in the last two days, his media has used every opportunity under the guise of virus and disease to stop people from casting their votes.

Recently, Irans Health Minister Saeed Namki dismissed claims of delay in reports. It was announced on government TV that this issue was immediately seen on February 19, while elections were to be held on February 21.

Five days after the election, the governments confirmed cases had risen to 139 and the death toll had reached 19. On the same day, Ahmed Amirabadi Farahani, a staunch MP from KOM, stood in Parliament and said that 50 people had died in his city in two weeks.

Deputy Health Minister Eraz Harirchi dismissed Farahanis claims and said he would resign if there were even 25 deaths.Later that day, Harirchi was seen sweating and coughing during the press conference on the coronavirus. He later declared that his test report was positive. In this way, he was the first of many high-profile politicians in Iran who had fallen prey to Corona.

Hariri is reportedly fully recovered and has also appeared live on TV on 13 March. Many experts and journalists have expressed fears that government figures are dangerous and that they are the result of trying to undermine the crisis present in Iran on a large scale.

In the investigation of BBC Persian, it was also found that the death toll is six times more than the official figures. But, even though government figures are constantly going up, the question is facing Iran that how to stop this virus?

Stay in lockdownAlirezas father passed away in mid-March. Alireza said, There was no one from our family when they buried my father. I could not even see him for the last time. He told us that he had died and buried him in a special zone in Tehrans main cemetery. has given.

Alirezas name has been changed for safety.Alirezas family asked the authorities not to gather a crowd for the funeral. However, he said that after burying his father, he can visit his grave once. However, when she reached the cemetery, the staff told them that it was not safe for them to come here as they are burying many more bodies there.

Alireza said, We talk about his fathers death more than his death. I am not a religious person, but I feel strange inside as if we have committed our fathers disrespect. Iranian authorities have now banned any large crowd for the last rites.

Many religious leaders, including the Supreme Guide, have issued religious orders. These fatwas have traditionally asked the body (Mordesur) of bodies to stop the bathing process of bodies to protect them from the virus.

While the WHO calls for immediate and aggressive measures at the international level, Irans response is moderate compared to the measures taken by China and Italy.

Schools, universities and seminars have been closed. Football matches have been canceled. A large number of disinfection operations are underway in the capital Tehran.

All Iranians have been advised not to travel and to stay at home. For the first time since the formation of the Islamic Republic in 1979, Friday prayers were also canceled.

Up to 1.55,000 prisoners have been temporarily released from overcrowded prisons to prevent the spread of the virus. They also include political prisoners. Many of them are thought to be in poor health. These include the Anglo-Iranian charity worker Nazneen Zagari-Ratcliffe.

However, most government buildings, offices and banks are open. Even retired teachers like the middle-class Irani Fateh and her husband (real names are hidden) say the problem is that people are still using money to buy groceries for fuel.

He said, We have to go to the bank to receive our monthly pension. We hope to receive a special allowance from Noroz in the next few days.

Many medical experts inside and outside Iran say the virus will continue to spread throughout the country until the government brings transparent data and brings the whole city to cities like KOM.

President Rouhani has repeatedly said that the government will not lock out cities and that all stores will remain open and that people will continue to work. It is a decision for which many believe Iran has no other option.

US sanctions have broken the back of the Iranian economy.The Pharisees New Year is the countrys largest annual festival, but Fateh says its not like celebrating this time. She says: All my life, I have never been alone in such a house on the occasion of Nowruz.

Even during the war, this did not happen when Saddam attacked our cities with missiles. time we were going. Her house to meet people on Nowruz.

Read more from the original source:
Coronavirus and the Blindness of Authoritarianism: A country hiding the tragedy of Coronavirus - World-Wire

Read More...

Big B Almost Believed ‘Blindness Is On Its Way’, Shatrughan Sinha Slams Mukesh Khanna for Mocking Sonaksh… – News18

Sunday, April 12th, 2020

Amitabh Bachchan has expressed concern over the condition of his vision. The veteran actor is afraid that he might just turn blind. "The eyes they see blurred images .. the vision reads double and for some days now I reconciled myself to the fact that blindness is on its way, to add to the million other medical problems that invest in me," expressing his concern, Bachchan wrote on his blog.

Read: Amitabh Bachchan Reveals He Almost Believed His 'Blindness Is On Its Way'

Mukesh Khanna, who played the role of Bhishma Pitamah in Mahabharat, recently took a dig at actress Sonakshi Sinha for not knowing for whom the Hanuman got the Sanjeevani booti. Reacting to the same, Sonakshi's actor turned politician father Shatrughan Sinha has slammed Khanna for taking a jibe at the actress.

Read: Shatrughan Sinha Slams Mukesh Khanna for Mocking Sonakshi, Asks What Qualifies Him as Expert on Ramayan

Raghava Lawrence confirmed Chandramukhi 2 with Rajinikanth on social media on Thursday. He added that he will be acting in the sequel of the 2005 horror-comedy alongside Rajinikanth while further revealing that he will also be donating Rs 3 crore towards coronavirus relief work.

Read: Raghava Lawrence Announces Chandramukhi 2 with Rajinikanth, Donates Rs 3 Cr for COVID-19 Relief Work

Rashami Desai has said that she congratulated her Bigg Boss 13 co-contestant Sidharth Shukla on the release of Bhula Dunga, a music video, where the latter featured with Shehnaz Gill. "We are cool with each other now. In fact, I wished him and Shehnaaz both after seeing their song Bhula Dunga," she said.

Read: Rashami Desai Talks About Her Equation with Sidharth Shukla, Arhaan Khan After Bigg Boss 13

Actor Shyam Sundar Kalani, who played the role of Sugriva and his brother Bali in the Ramanand Sagars Ramayan has passed away. He cause and date of his demise is not yet known.

Read: Shyam Sundar Kalani, Who Played Sugriva and Bali in Ramayan, Passes Away

Follow @News18Movies for more

Excerpt from:
Big B Almost Believed 'Blindness Is On Its Way', Shatrughan Sinha Slams Mukesh Khanna for Mocking Sonaksh... - News18

Read More...

We still don’t have our LGBTQ rights. What are we going to do about it? – LGBTQ Nation

Sunday, April 12th, 2020

Everyone remembers Obergefell v. Hodges. Thousands of people from around the country went out to the streets to fight for their right to love who they want to love. And they won! The Supreme Court ruling legalized marriage across the whole country, and everyone celebrated this massive event in not only the history of the LGBTQ community but the history of the world.

People looked forward to what was next; maybe it would be the Equality Act, maybe letting people choose the bathrooms that align with their gender, or even the legal recognition of non-binary people federally. But there was nothing. There were some wins here and there, but there havent been any action nearly as big since 2015. Why?

Related: Stonewall sparked much more than the gay rights movement & you probably had no idea

Its not that we dont need these big actions anymore; there are still so many issues affecting LGBTQ people around the world.

We still dont have protection from discrimination on the basis of sexual orientation federally, let alone for gender identity. So a man can get married to his husband, then turned away by the baker of their wedding cake, fired from his job, and kicked out of his apartment. When they get on their feet, they can be denied adopting a child.

If someones trans, they could be forced to use the wrong bathroom, barred from sports, and misgendered at the DMV, in addition to job and other forms of discrimination.

However, even a lot of the rights we take for granted, like to be open about being gay with others, are still not allowed in many countries. Theres a blindness in the U.S. to the problems of other countries.

According to the 2019 ILGA State-Sponsored Homophobia Report, there are still 68 countries where same-sex intercourse is illegal. In 11 of these countries, someone could get the death penalty.

Only 26 countries allow for same-sex marriage, which is only 13% of the United Nations.

Not only are things already bad, but theyre getting worse. According to the Equality Federations Equality tracker, there are over 200 bills in state legislatures in the U.S. that would negatively impact the LGBTQ community, and no one is talking about them. Some of these allow tax dollars to go to discriminatory adoption centers, others will ban trans athletes from competing as their gender. Some state-level bills will prevent cities and counties from passing anti-discrimination laws.

Take the Missouri HB 2303. It essentially says that transgender students at public schools have to use the bathroom that aligns with the sex on their birth certificate. It is an incredibly important bill, but if you search for it on Google News, there is only one result, and its briefly mentioned as part of a list.

If we dont fight for these issues, not only will nothing get better, but it will start getting worse.

Why arent these issues at the top of our minds? One reason is that were just complacent. Maybe we dont want to rock the boat, as if were lucky we have what we already have.

This is a dangerous position. Imagine what wouldve happened if we stopped after sodomy laws were revoked. Who knows how long it wouldve been until we got rights.

We also are privileged to live in a wealthy country, and it can shield us from the problems of the rest of the world. Just the fact youre reading this means you probably have access to the internet, have a computer or a phone, and live in a country with a free press.

Lastly, something could be said about branding. Think about the marriage equality protests. Everything was iconic, from the slogans like Love is love to the symbols like the rainbow flag or the red equals sign. All you would have to do is put a rainbow bumper sticker on your car and immediately everyone would know that you support LGBTQ rights, and it puts the thought of marriage equality in their heads. It was the constant exposure that gave the issue attention. There hasnt been anything like that for the problems we face now.

So what can we do to get any change to happen? The first thing we can do is talk about it. Get it in peoples thoughts. Maybe make post on Facebook or Twitter. The more people that talk about, the more others think about it and the more normal it feels.

There is a psychological effect known as the familiarity heuristic, where people generally feel more comfortable with things that they are familiar with, and that can apply to this situation.

Also, there needs to be better branding. No one is going to read a bumper sticker that says, Affirming the gender identity of a student is important and the supposed advantage that transgender women have in sports is scientifically debatable, dependent on numerous factors that can be addressed with policies other than outright bans, and really not important compared to protecting young people from discrimination. Try something like Let girls play or Trans women = women.

By implementing these strategies, the LGBTQ community could make an impact, and faster than ever.

Read more:
We still don't have our LGBTQ rights. What are we going to do about it? - LGBTQ Nation

Read More...

Page 25«..1020..24252627..30..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick